Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

China flag China · Delayed Price · Currency is CNY
14.92
-0.23 (-1.52%)
Apr 25, 2025, 3:00 PM CST
0.13%
Market Cap 22.29B
Revenue (ttm) 8.50B
Net Income (ttm) 955.59M
Shares Out 1.49B
EPS (ttm) 0.64
PE Ratio 23.33
Forward PE 18.52
Dividend 0.53 (3.55%)
Ex-Dividend Date Mar 26, 2025
Volume 10,853,504
Average Volume 13,877,452
Open 15.21
Previous Close 15.15
Day's Range 14.89 - 15.23
52-Week Range 12.24 - 17.77
Beta 0.44
RSI 46.15
Earnings Date Apr 29, 2025

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China. [Read more]

Sector Healthcare
Founded 1994
Employees 10,958
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600535
Full Company Profile

Financial Performance

In 2024, SHA:600535's revenue was 8.50 billion, a decrease of -2.03% compared to the previous year's 8.67 billion. Earnings were 955.59 million, a decrease of -10.78%.

Financial Statements

News

There is no news available yet.